The FLCN gene, a tumor suppressor, is strongly implicated in the autosomal dominant Birt-Hogg-Dubé syndrome (BHD) syndrome, which is characterized by lung cysts, benign skin tumors and kidney cancer.

A "groundbreaking" cancer treatment trial by Memorial Sloan Kettering shows immunotherapy alone can eliminate some tumors, offering patients an alternative to chemotherapy and surgery.